arrow
N

Naoya Kato

Nagasaki University
H指数:23
被引数:3,777

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells

FcBP-HFQ脂质介导的曲妥珠单抗修饰对负载mRNA的脂质纳米粒的递送至HER2表达癌细胞的增强

2026-08-180
OAAI
Immunopeptidomics combined with full-length transcriptomics uncovers diverse neoantigens
2025-12-010
OAAI
Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles

利用取向可控的PD-L1抗体修饰脂质纳米颗粒靶向递送VEGF-siRNA至胶质母细胞瘤

2025-10-040
OAAI
Nationwide survey of patients with acute liver failure and late-onset hepatic failure in Japan seen between 2016 and 2021

日本急性肝衰竭和迟发性肝衰竭患者的全国调查见2016年和2021

2025-04-010
OA
MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinoma
2025-02-010
PRE
Efficacy of Magnifying Texture and Color Enhancement Imaging With Indigo Carmine as an Alternative to Crystal Violet for Colorectal Tumors

靛蓝胭脂红替代结晶紫的放大纹理和颜色增强成像对结直肠肿瘤的疗效

2025-01-140
PRE
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy
2024-10-290
OAAI
A prediction model of abnormal acid reflux in gastroesophageal reflux disease

胃食管反流病异常酸反流的预测模型

2024-05-150
PRE
Investigation of risk factors for metachronous recurrence in patients with early gastric adenocarcinoma by miRNA-mRNA integral profiling
2023-11-110
OAAI
Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
2023-11-010
OA
Long-term course of gastric submucosal tumors: growth speed and size-increasing factors
2023-06-013
PRE